Despite mounting evidence that PCSK9 inhibitors can lower cholesterol levels and reduce the risk of cardiovascular disease, the basic processes underpinning PCSK9 inhibitors' effects on cardiac function have not been studied enough and it requires further research [16,17]. This evidence concerns the gene PCSK9 and cardiovascular disorder.